CONTENIDO WEB

Dolor agudo en gatos: investigación nociceptiva y nuevas terapias

Descripción: Tesis de master centrada en el uso de la una nueva formulación de buprenorfina concentrada (1,8 mg/mL) para el control del dolor en gatos. A diferencia de las formulaciones habituales, este fármaco administrado SC tiene una pauta de administración de 24 h.

TITULO FUENTE ORIGINAL:

Acute pain in domestic cats: nociceptive investigation and novel therapeutics

ORGANIZACIÓN:

Universidad de Montreal

ENLACE: https://papyrus.bib.umontreal.ca/xmlui/bitstr[...]

Analgesic drug availability is limited in feline practice. The aim of these studies was to investigate the antinociceptive properties of a novel formulation of buprenorphine (Simbadol, 1.8 mg ml-1 ) and tapentadol in cats. In two separate studies, six healthy cats (each) were included in a prospective, randomised, blinded, crossover study. In study I, Simbadol (1.8 mg... + Leer más

Analgesic drug availability is limited in feline practice. The aim of these studies was to investigate the antinociceptive properties of a novel formulation of buprenorphine (Simbadol, 1.8 mg ml-1 ) and tapentadol in cats. In two separate studies, six healthy cats (each) were included in a prospective, randomised, blinded, crossover study. In study I, Simbadol (1.8 mg mL-1) was administered by various routes: subcutaneous (SC; 0.24 mg kg-1), intravenous (IV; 0.12 mg kg-1) or buccal (OTM; 0.12 mg kg-1) route of administration and thermal thresholds (TT) were compared with a saline group (SAL; saline SC). Plasma buprenorphine and norbuprenorphine concentrations were measured up to 72 hours following each buprenorphine treatment. A bespoke pharmacokinetic-pharmacodynamic model fitted data from two analytes/three routes of administration. In study II, thermal thresholds were compared among cats receiving buprenorphine (0.02 mg kg−1, IM), placebo (50 mg oral dextrose) and two doses of oral tapentadol (low-dose 25 mg; high-dose 50 mg). Subcutaneous administration of Simbadol provided long-lasting thermal antinociception (≥ 24 hours). These effects are prolonged compared with the IV (8 hours) and OTM (12 hours) treatments. Joint pharmacokinetic-pharmacodynamic modelling demonstrated prolonged plasma concentrations for the SC route. Both doses of tapentadol increased thermal antinociception in cats. The high-dose of tapentadol produced similar duration of antinociception as intramuscular buprenorphine (2 hours) and twice as long as the low-dose. Palatability presented a significant limitation to the drug’s administration. Simbadol and tapentadol produced thermal antinociception when compared with saline. Additional investigation is necessary to determine if this translates to the clinical setting.

- Leer menos

ENLACES DE INTERÉS

Enlace al texto de acceso libre:: https://papyrus.bib.umontreal.ca/xmlui/bitstr[...]